ZURA vs. RLAY, SRRK, PRME, RGNX, CRGX, ITOS, HLVX, VALN, TSHA, and KYTX
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Relay Therapeutics (RLAY), Scholar Rock (SRRK), Prime Medicine (PRME), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), iTeos Therapeutics (ITOS), HilleVax (HLVX), Valneva (VALN), Taysha Gene Therapies (TSHA), and Kyverna Therapeutics (KYTX). These companies are all part of the "biological products, except diagnostic" industry.
Relay Therapeutics (NASDAQ:RLAY) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.
In the previous week, Zura Bio had 1 more articles in the media than Relay Therapeutics. MarketBeat recorded 7 mentions for Zura Bio and 6 mentions for Relay Therapeutics. Zura Bio's average media sentiment score of 1.22 beat Relay Therapeutics' score of 0.62 indicating that Relay Therapeutics is being referred to more favorably in the media.
Zura Bio has a net margin of 0.00% compared to Zura Bio's net margin of -1,263.49%. Zura Bio's return on equity of -42.66% beat Relay Therapeutics' return on equity.
Relay Therapeutics presently has a consensus price target of $22.20, indicating a potential upside of 246.33%. Zura Bio has a consensus price target of $18.83, indicating a potential upside of 258.73%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Relay Therapeutics.
97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 4.3% of Relay Therapeutics shares are owned by insiders. Comparatively, 15.8% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Zura Bio has lower revenue, but higher earnings than Relay Therapeutics.
Relay Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.
Relay Therapeutics received 28 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 60.94% of users gave Relay Therapeutics an outperform vote.
Summary
Relay Therapeutics and Zura Bio tied by winning 8 of the 16 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
